⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29262605 | 0.97 | — | — | |
| SCHEMBL1646471 | 0.88 | CA1 (0.95) | — | |
| SCHEMBL1644220 | 0.88 | — | — | |
| SCHEMBL16479547 | 0.87 | CA1 (0.60) | — | |
| SCHEMBL3196672 | 0.87 | CA1 (0.60) | — | |
| SCHEMBL964315 | 0.86 | CA1 (1.00) | — | |
| SCHEMBL22169773 | 0.86 | CA1 (1.00) | — | |
| SCHEMBL9069907 | 0.84 | CA1 (0.95) | — | |
| SCHEMBL18692966 | 0.82 | CA1 (0.60) | — | |
| SCHEMBL3225545 | 0.82 | CA1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | claimed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | claimed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | claimed |
| US-11471455-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2022-10-18 | — | — | US | claimed |
| EP-3860984-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | claimed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | claimed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | claimed |
| EP-3728214-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2020-10-28 | — | — | EP | claimed |
| CN-111727185-A | Substituted N-heterocyclyl-and N-heteroaryltetrahydropyrimidines and their salts and their use as herbicidal active substances | 拜耳公司 | 2020-09-29 | — | — | CN | claimed |
| WO-2020070088-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-09 | — | — | WO | claimed |
| US-20200079765-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-12 | — | — | US | claimed |
| EP-3558975-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | Bayer CropScience Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| WO-2019025153-A1 | USE OF SUBSTITUTED N-SULFONYL-N'-ARYL DIAMINOALKANES AND N-SULFONYL-N'-HETEROARYL DIAMINOALKANES OR SALTS THEREOF FOR INCREASING THE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| WO-2018114596-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | claimed |
| CN-116262735-B | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-116262724-B | Novel oxo-pyridine compound and preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-117956992-A | MENIN-MLL interaction inhibitors | 赛达克斯制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |